A class 1A antiarrhythmic agent, procainamide exhibits cardiac action similar to that of quinidine. It is considered both a supraventricular and ventricular antidysrhythmic. Procainamide prolongs the refractory times in both the atria and ventricles, decreases myocardial excitability, and depresses automaticity and conduction velocity. It has anticholinergic properties that may contribute to its effects. Procainamide’s effects on heart rate are unpredictable, but it usually causes only slight increases or no change. It may exhibit negative inotropic actions on the heart, although cardiac outputs are generally not affected. On ECG, QRS widening, and prolonged PR and QT intervals can be seen. The QRS complex and T wave may occasionally show some slight decreases in voltage.
In veterinary medicine, procarbazine is used as part of MOPP protocols (mechlorethamine, vincristine, procarbazine, prednisone) to treat lymphomas in dogs and cats. It may be of benefit in treating granulomatous meningoencephalitis (GME) in dogs.
劑量數字暫停提供:VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容,DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源;計算機可手動輸入劑量換算。
公開獸醫資料可支持專科犬隻抗心律不整角色與犬/馬分途徑參考值,犬原始研究則只支持特定製劑的藥物動力學;但不足以建立通用計算器、貓療程、產品互換、自動交互作用規則、血中濃度目標、副作用發生率、生殖安全結論或飼主可自行執行指示。所有數值卡均只留稽核。
依出現頻率分組;嚴重副作用獨立列出,臨床上需立即辨識。
85%
0.5 hours
renal